NeuroVision is engaged in clinical trials globally seeking to aid in disease diagnosis through retinal imaging.

Cognitive Health in Ageing Register: Investigational, Observational and Trial Studies in Dementia Research (CHARIOT): Prospective Readiness Cohort Study (PRO) Identifier: NCT02114372

  • Main Study: To describe the baseline characteristics (including demographics, cognitive status, and other measures) and the cognitive and functional changes of persons at risk for developing Alzheimer’s disease (AD).
  • Neurovision Ancillary Study: To explore correlation between retinal amyloid beta plaques identified by fluorescence with amyloid positron emission tomography (PET) Standardized Uptake Value Ratio (SUVR) and cerebrospinal fluid (CSF) amyloid beta 42 testing in participants at risk for Alzheimer’s dementia.

A cross-sectional study to evaluate the ability to detect retinal amyloid-beta plaques utilizing the EidonTM (RetiaTM) retinal imaging system with and without curcumin labeling in participants with Mild Cognitive Impairment (MCI), and healthy controls
ANZCTR Trial ID: ACTRN12616001679471p

Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease Identifier: NCT02008357

  • Main Study: The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer Disease [AD]).
  • SubStudy: [1] To characterize retinal amyloid in subjects with preclinical AD prior to administration of experimental treatment received in the primary A4 study protocol. [2] To characterize the longitudinal trajectory of retinal amyloid in subjects with preclinical AD. [3] To correlate retinal amyloid with brain amyloid and cognitive change.